Palantir stock slips despite Citi upgrade as Feb. 2 earnings loom

Palantir stock slips despite Citi upgrade as Feb. 2 earnings loom

New York, January 13, 2026, 10:42 ET — Regular session

  • Palantir shares slipped roughly 1.2% in morning trading, underperforming the broader U.S. benchmarks, which fell about 0.4%
  • Citi upgrades its rating to Buy and boosts the target price to $235
  • Palantir will release its fourth-quarter results after the market closes on Feb. 2

Palantir Technologies Inc. shares dropped roughly 1.2% to $177.22 Tuesday morning, lagging a mild pullback in U.S. stocks. The software company is buoyed by an analyst upgrade, while investors keep a close watch on its upcoming earnings release.

Citi analyst Tyler Radke raised Palantir to Buy from Neutral and boosted his price target to $235 from $210, citing a pickup in enterprise demand and the possibility of a government defense spending “supercycle.” Citi forecasts Palantir could see 70% to 80% revenue growth by 2026. “We are upgrading PLTR to Buy/High-Risk from Neutral and raising estimates,” the note said, per Seeking Alpha. (TipRanks)

Palantir announced Monday it will release its fourth-quarter and full-year 2025 results after the market closes on Feb. 2. The stock’s sharp rally has sent its valuation into unusual territory, setting up the upcoming earnings as a key check on whether demand can sustain that momentum. (Business Wire)

Radke’s argument hinges on moving beyond pilot projects to full-scale rollouts, especially in sectors like healthcare and defense, along with broader adoption of Palantir’s Artificial Intelligence Platform, or AIP. Simply put, the expectation is that initial trials will convert into sizable repeat contracts that noticeably boost revenue.

Palantir announced it will hold a webcast at 5 p.m. ET and respond to shareholder questions via an online portal. The company did not release any preliminary results in the statement. (Business Wire)

Palantir provides software that helps government agencies and companies integrate and analyze data. The company has been ramping up efforts with commercial clients but still relies heavily on its sizable government contracts, which can fluctuate with their timing. (Yahoo Finance)

Tuesday’s drop makes it clear the market isn’t handing out freebies after the upgrade. Over the past year, investors have been willing to pay a premium for firms linked to enterprise AI spending, and Palantir is one of those stocks where the key question is how much of that optimism is already baked in.

Still, the setup works both ways. The stock trades at a hefty premium to the broader market, so a stumble in growth, margins, or deal conversion rates could quickly weigh on the shares—even if the long-term outlook remains unchanged.

Investors are focused on whether commercial momentum holds steady and any updates on government demand along with its pipeline. Expect guidance to carry more weight than the headline numbers for the quarter.

Palantir’s next major event is Feb. 2, with the earnings report coming after the market closes and a webcast scheduled for later that night.

Stock Market Today

  • Pinnacle rings NYSE opening bell after Synovus merger
    January 13, 2026, 1:30 PM EST. Pinnacle Financial Partners rang the NYSE opening bell on Tuesday after finalizing its merger with Columbus-based Synovus. The $8.6 billion deal, completed Jan. 2, creates a single holding company and positions the combined firm among the nation's largest regional banks, according to NYSE officials. CEO Kevin Blair, Chairman Terry Turner and Chief Development Officer Chris Taylor led the ceremony; Blair previously served as Synovus CEO and president. The merged bank now operates under the Pinnacle name, underscoring the expanded footprint of the two firms.
Oracle stock slips in regular trade despite Goldman buy call as AI buildout stays in focus
Previous Story

Oracle stock slips in regular trade despite Goldman buy call as AI buildout stays in focus

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next
Next Story

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

Go toTop